Answer
No. Its licensed role is as an add-on to ravulizumab or eculizumab; effectiveness as monotherapy has not been established.
Sources for this answer
- Voydeya 100mg film-coated tabletemc · SmPC Current selected SmPC · Version 3
loading page…
Explore the tools and reference material available on iatroX.
Explore askiatroX